SequelSEC

CorMedix Inc. CRMD

Pharmaceutical Preparations · CIK 0001410098 · Fiscal year ends 1231

AnnualQuarterlyTTM
Revenue
$101.93M
Fiscal year ended 2026-06-30
Operating income
$42.91M
Fiscal year ended 2026-06-30
Free cash flow
$85.68M
Fiscal year ended 2026-06-30

CorMedix Inc. (CRMD) reported revenue of $101.93M and net income of $25.99M for the fiscal year ended 2026-06-30. This page shows 10 annual periods of income statement, balance sheet and cash flow figures normalized from CorMedix Inc.’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Pharmaceutical Preparations.

Income

CorMedix Inc. income by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-312024-09-302024-06-302022-12-31
Revenue$101.93M$127.43M$128.62M$104.28M$39.74M$39.08M$31.21M$11.46M$806.12K$29.70K
Cost of revenueUnavailableUnavailable$11.17MUnavailable$1.86M$1.54M$1.12M$634.65K$509.84K$406
Gross profit$77.13MUnavailable$107.31MUnavailable$37.87M$37.48M$30.03M$10.77M$296.28K$29.30K
Operating income$42.91M$63.66M$59.13M$51.35M$19.54M$20.12M$12.94M-$3.29M-$15.30M-$8.39M
Net income$25.99M$38.60M$14.02M$108.56M$19.83M$20.64M$13.46M-$2.78M-$14.15M-$8.21M
Research & development$6.68M$7.21M$8.60M$5.10M$2.44M$3.19M$1.73M$727.12K$650.99K$2.84M
Weighted-average diluted sharesshares 92.48Mshares 92.98MUnavailableshares 86.21Mshares 71.92Mshares 68.98MUnavailableshares 58.83Mshares 57.62MUnavailable
Pretax income$38.73M$55.64M$56.45M$52.58M$20.35M$20.64M$13.46M-$2.78M-$14.15M-$8.21M
Income tax expense$12.74M$17.04M$42.43M-$55.99M$522.00K$0-$230$0Unavailable$0
Diluted EPS$0.29$0.43Unavailable$1.26$0.28$0.30Unavailable$-0.05$-0.25Unavailable
Selling, general & administrative$27.53M$34.25M$39.58M$36.64M$15.89M$14.17M$15.37M$13.33M$14.95M$5.58M
General & administrative$15.08M$21.72M$23.57M$25.45M$9.50M$9.69M$7.11M$6.58M$7.56MUnavailable
Selling & marketing$12.45M$12.53M$16.01M$11.19M$6.38M$4.47M$8.26M$6.75M$7.39MUnavailable

Balance

CorMedix Inc. balance by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-312024-09-302024-06-302022-12-31
Cash & equivalents$256.69M$178.09M$144.84M$48.49M$159.31M$66.29M$40.65M$35.29M$28.54M$43.15M
Total assets$904.05M$815.64M$826.14M$750.86M$252.60M$149.58M$118.85M$77.59M$57.73M$62.04M
Current assets$480.55M$383.11M$367.05M$259.54M$248.06M$144.86M$114.58M$73.15M$53.19M$59.55M
Total liabilities$443.22M$378.59M$420.84M$376.73M$31.97M$34.69M$34.19M$18.87M$11.55M$6.98M
Current liabilities$187.40M$128.78M$174.27M$133.64M$31.71M$34.39M$33.84M$18.48M$11.11M$6.31M
Total equity incl. NCI$460.83M$437.05M$405.31M$374.13M$220.63M$114.89M$84.66M$58.71M$46.18M$55.06M
Temporary (mezzanine) equityUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Inventory$38.58M$30.73M$29.72M$28.92M$9.63M$7.49M$7.60M$6.65M$4.01MUnavailable
Accounts receivable$161.30M$154.81M$171.23M$158.57M$42.91M$54.61M$51.65M$17.39M$206.34KUnavailable
Goodwill$30.00M$30.00M$30.00M$17.52MUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Long-term debtUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Accounts payable$10.24M$12.83M$7.88M$20.45M$5.82M$1.93M$1.72M$1.34M$3.34M$2.20M

Cash flow

CorMedix Inc. cash flow by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-312024-09-302024-06-302022-12-31
Operating cash flow$86.24M$42.38M$94.46M$30.86M$29.99M$19.74M-$5.61M-$13.65MUnavailable-$6.15M
Capital expenditures$561.00K$729.00K$1.72M$505.90K$24.00K$10.00K$10.14K$9.77KUnavailable$128.76K
Investing cash flow-$561.00K$2.96M$3.30M-$291.32M-$20.21M-$195.00K-$303.87K$6.32MUnavailable-$1.86K
Financing cash flow-$7.07M-$12.10M-$1.41M$150.53M$83.24M$6.09M$11.29M$14.07MUnavailable$6.05M
Net change in cash$78.60M$33.25M$96.34M-$109.93M$93.02M$25.64M$5.36M$6.75MUnavailable-$95.33K
Stock-based compensation$4.08M$4.58M$3.59M$4.07M$2.68M$3.50M$1.19M$1.23M$1.26M$874.05K
Common dividends paidUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Common share repurchases$6.39M$11.09MUnavailableUnavailable$0$0UnavailableUnavailableUnavailableUnavailable
Depreciation & amortization$10.54M$10.54MUnavailableUnavailable$163.00K$162.00KUnavailableUnavailableUnavailableUnavailable

Derived

CorMedix Inc. derived by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-312024-09-302024-06-302022-12-31
Free cash flow$85.68M$41.65M$92.74M$30.35M$29.97M$19.73M-$5.63M-$13.66MUnavailable-$6.28M
Gross margin75.7%Unavailable83.4%Unavailable95.3%95.9%96.2%94.0%36.8%98.6%
Operating margin42.1%50.0%46.0%49.2%49.2%51.5%41.4%-28.7%-1898.1%-28244.7%
FCF margin84.1%32.7%72.1%29.1%75.4%50.5%-18.0%-119.2%Unavailable-21155.5%
SBC / revenue4.0%3.6%2.8%3.9%6.7%9.0%3.8%10.7%156.8%2942.7%
Current ratio2.56x2.98x2.11x1.94x7.82x4.21x3.39x3.96x4.79x9.44x
Revenue YoY growth156.5%226.1%312.1%810.2%4829.3%UnavailableUnavailableUnavailableUnavailable-47.3%
Net margin25.5%30.3%10.9%104.1%49.9%52.8%43.1%-24.2%-1755.5%-27637.7%
R&D / revenue6.6%5.7%6.7%4.9%6.1%8.2%5.5%6.3%80.8%9572.5%
CapEx / revenue0.6%0.6%1.3%0.5%0.1%0.0%0.0%0.1%Unavailable433.5%
Long-term debt / equityUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Effective tax rate32.9%30.6%75.2%-106.5%2.6%0.0%-0.0%UnavailableUnavailableUnavailable

Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open CRMD in the interactive workspace to inspect any figure back to its filing.

Source filings

10-Q · Filed 2026-08-13View SEC filing
10-Q · Filed 2026-05-14View SEC filing
10-K · Filed 2026-03-05View SEC filing
10-Q · Filed 2025-11-12View SEC filing
10-Q · Filed 2025-08-07View SEC filing
10-Q · Filed 2025-05-06View SEC filing

Companies in the same industry

Reconciliation checks needing review

2 periods on this page do not reconcile under this site’s normalization. Read that as a limitation here before an observation about the company: the figures are the filer’s own, the filings linked above are authoritative, and a difference usually means the concepts this site selected do not match how this filer presents its statements. Nothing is adjusted to make a check pass.

gross profit bridgeinconsistent2026-03-31

Withheld: cost revenue could not be reconciled with the rest of this filer’s statement.

gross profit bridgeinconsistent2025-09-30

Withheld: cost revenue could not be reconciled with the rest of this filer’s statement.